Results 131 to 140 of about 743,467 (306)

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

open access: yesMolecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou   +12 more
wiley   +1 more source

The mean sensitivity, specificity, positive predictive value and negative predictive value of SCLIWC in single Weibo status scoring (N = 11).

open access: yes, 2016
The mean sensitivity, specificity, positive predictive value and negative predictive value of SCLIWC in single Weibo status scoring (N = 11).
Dongdong Jiao (2847353)   +3 more
core   +1 more source

The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma. [PDF]

open access: yesBMC Urol, 2022
Yamasaki M   +14 more
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

open access: yesMolecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi   +7 more
wiley   +1 more source

Screening test performance: estimated corrected positive predictive value and negative predictive values.

open access: yes, 2013
CIN2+ = CIN2/CIN3/ICC, CIN3+ = CIN3/ICC, PPV = Positive predictive value, NPV = Negative predictive value, CI = Confidence interval, Cytology = Cytology Pap smear, HPV = HPV DNA, VIA = Visual inspection with 5% acetic acid.*Cytology negative: normal/LSIL/
Simon Levin (289528)   +13 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures

open access: yes, 2011
Background: Current prognostic gene signatures for breast cancer mainly reflect proliferation status and have limited value in triple-negative (TNBC) cancers.
Pusztai, Lajos   +44 more
core   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen   +14 more
wiley   +1 more source

Assessment of two researchers on the CLE images, including the average sensitivity, specificity, positive predictive value, negative predictive value and accuracy.

open access: yes, 2014
Abbreviations: CLE, confocal laser endomicroscopy; PPV, positive predictive value; NPV, negative predictive value.Assessment of two researchers on the CLE images, including the average sensitivity, specificity, positive predictive value, negative ...
Lei Cui (165714)   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy